scholarly article | Q13442814 |
P50 | author | Luke Norton | Q51373612 |
Ralph A. DeFronzo | Q58689309 | ||
P2093 | author name string | G Clarke | |
R E J Ryder | |||
M Abdul-Ghani | |||
R Chilton | |||
P2860 | cites work | Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 |
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study | Q28281870 | ||
10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. | Q30903369 | ||
Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus | Q33786881 | ||
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 | ||
Thiazolidinediones | Q34346862 | ||
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy | Q34430674 | ||
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study | Q34494252 | ||
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone | Q34543009 | ||
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study | Q34626189 | ||
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes | Q35548033 | ||
Dapagliflozin lowers plasma glucose concentration and improves β-cell function | Q35578244 | ||
Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition | Q35973255 | ||
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy | Q36047253 | ||
Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study' | Q36073447 | ||
The effects of thiazolidinediones on blood pressure levels - a systematic review | Q36545395 | ||
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack | Q36953272 | ||
Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial | Q36972810 | ||
Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis | Q37106685 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates | Q37251096 | ||
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 | ||
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors | Q37505281 | ||
Risk of fractures with glitazones: a critical review of the evidence to date | Q37520986 | ||
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis | Q37683205 | ||
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. | Q37878715 | ||
Thiazolidinediones and fracture risk in patients with Type 2 diabetes | Q37889370 | ||
Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction | Q37961085 | ||
Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus | Q38005020 | ||
Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus | Q38408749 | ||
Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers | Q38410283 | ||
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis | Q38417421 | ||
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial | Q38473723 | ||
Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus | Q38638523 | ||
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion | Q39554276 | ||
Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes | Q41107308 | ||
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 | ||
Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes | Q42518121 | ||
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients | Q44018167 | ||
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial | Q44251536 | ||
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms | Q44272913 | ||
Thiazolidinediones and blood lipids in type 2 diabetes | Q44542266 | ||
A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors | Q45124693 | ||
Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. | Q46024732 | ||
Thiazolidinedione use and the risk of fractures. | Q46052082 | ||
Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). | Q46552257 | ||
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia | Q46570674 | ||
Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption | Q46592677 | ||
Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes | Q46966704 | ||
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. | Q51335341 | ||
Rosiglitazone decreases albuminuria in type 2 diabetic patients. | Q51463962 | ||
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
The effect of pioglitazone on the liver: role of adiponectin. | Q51488911 | ||
Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. | Q51497865 | ||
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. | Q51552529 | ||
P433 | issue | 5 | |
P304 | page(s) | 454-462 | |
P577 | publication date | 2016-04-06 | |
P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
P1476 | title | Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor | |
P478 | volume | 18 |
Q88758014 | A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice |
Q39000587 | Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies |
Q92813444 | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial |
Q100946503 | Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors |
Q38778064 | Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus |
Q47696671 | Pharmacological management of type 2 diabetes: what's new in 2017? |
Q30250347 | The current role of thiazolidinediones in diabetes management |
Q38708422 | The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia |
Q89881026 | The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety |
Q90781399 | The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner |
Search more.